Ameritas Investment Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Ameritas Investment Partners’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-265	Closed	-$8K	–	3183
2022 Q1	$8K	Hold	265	–	–	﹤0.01%	2861
2021 Q4	$11K	Hold	265	–	–	﹤0.01%	2869
2021 Q3	$19K	Hold	265	–	–	﹤0.01%	2735
2021 Q2	$30K	Hold	265	–	–	﹤0.01%	2503
2021 Q1	$27K	Hold	265	–	–	﹤0.01%	2430
2020 Q4	$13K	Buy	265 +170	+179%	+$6.24K	﹤0.01%	2687
2020 Q3	$3K	Hold	95	–	–	﹤0.01%	3048
2020 Q2	$4K	Hold	95	–	–	﹤0.01%	2997
2020 Q1	$5K	Hold	95	–	–	﹤0.01%	2820
2019 Q4	$4K	Hold	95	–	–	﹤0.01%	2925
2019 Q3	$4K	Hold	95	–	–	﹤0.01%	2962
2019 Q2	$5K	Buy	+95	New	+$7.9K	﹤0.01%	2948
2018 Q2	–	Sell	-16	Closed	-$1K	–	3036
2018 Q1	$1K	Hold	16	–	–	﹤0.01%	2942
2017 Q4	$1K	Hold	16	–	–	﹤0.01%	2952
2017 Q3	$1K	Hold	16	–	–	﹤0.01%	2980
2017 Q2	$2K	Buy	+16	New	+$1.82K	﹤0.01%	2982

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Ameritas Investment Partners's IMDX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 265 shares — an estimated $8K sold.

Ameritas Investment Partners first reported a position in IMDX in Q2 2017 and held it in 16 quarters. The position peaked at $30K in Q2 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

Ameritas Investment Partners reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
Ameritas Investment Partners sold 265 Insight Molecular Diagnostics shares in Q2 2022, an estimated $8K.
Ameritas Investment Partners first reported a position in Insight Molecular Diagnostics in Q2 2017 and held it in 16 quarters.
Ameritas Investment Partners's Insight Molecular Diagnostics position peaked at $30K in Q2 2021.
75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.